Dr. Aaron McGeagh, MD, MSc
Family Medicine Physician | Clinical Research Fellow, University of British Columbia | 13 Years Clinical Experience
Published: November 2025
The Short Answer
Here’s the uncomfortable truth: most doctors never learned about peptides in medical school. Not because peptides aren’t important—they’re actually one of the fastest-growing areas in therapeutic research—but because medical education moves at a glacial pace while science races ahead.
When you ask your family doctor about BPC-157 or growth hormone secretagogues, that blank look isn’t incompetence. It’s a systemic gap that’s been decades in the making.
The Real Problem With Medical Education
Medical school crams an impossible amount of information into four years. Every specialty fights for curriculum time. Every new discovery competes with established knowledge that students absolutely must master before graduation.
Peptides occupy this weird no-man’s-land between biochemistry, pharmacology, and clinical medicine. Students learn amino acid chemistry in first year, pharmacokinetics in second year, and clinical applications in their final years—but peptides require understanding all of these simultaneously. The system isn’t built for that kind of integration.
So unless you specialized in endocrinology or oncology, you probably encountered peptides for about fifteen minutes during a biochemistry lecture. And those lectures focused on insulin and glucagon, not the synthetic therapeutic peptides that have exploded in popularity.
This Should Sound Familiar
Remember how doctors supposedly don’t know anything about nutrition?
Same problem. Different subject.
Back in 1985, the National Academy of Sciences recommended medical schools provide at least 25 hours of nutrition education. Four decades later, most schools still don’t meet that threshold. A 2023 survey found that 58% of medical students received zero formal nutrition education during their entire training.
The pattern repeats with peptides:
- Both fall outside traditional pharmaceutical curricula
- Both require crossing disciplinary boundaries
- Both have massive patient interest that outpaces physician knowledge
- Both struggle to find qualified faculty who can teach the material
When the American Academy of Family Physicians pulled CME credits from certain integrative medicine courses in 2014, it created a chilling effect. Institutions got cautious. Physicians got nervous. And the knowledge gap widened.
The Regulatory Minefield
Peptides exist in a bizarre regulatory space that makes even informed physicians hesitate.
In Canada, Health Canada has expressed concerns about compounding certain peptides—particularly GLP-1 receptor agonists. They consider some compounding activities to be “manufacturing” rather than traditional pharmacy work, which triggers completely different regulatory requirements. Pharmacies must navigate both federal and provincial rules that vary across the country.
Many popular peptides—BPC-157, CJC-1295, Ipamorelin—have never received Health Canada approval for any indication. They exist in a grey zone where they can be legally sold as research chemicals but aren’t approved for human therapeutic use.
This creates genuine professional risk for physicians. Medical licensing bodies may investigate doctors who prescribe unapproved compounds. Malpractice insurance may not cover adverse outcomes from treatments outside standard practice. Even if these concerns rarely materialize, they absolutely influence how physicians respond to patient inquiries.
Why Your Doctor Cares So Much About “Evidence”
Physicians are trained to worship at the altar of randomized controlled trials. This framework protects patients from ineffective treatments, but it creates real problems when evaluating peptides.
Take BPC-157. It has over 100 animal studies demonstrating wound healing, tissue protection, and anti-inflammatory effects. A systematic review found consistent positive results across rodent models for muscle, tendon, and bone healing. But human clinical trials? Extremely limited.
One Phase I trial began in 2015 but the researchers cancelled submission of results in 2016. A small retrospective study of 12 patients with knee pain reported that 11 experienced significant relief—but without control groups or standardized measures, this carries little weight in traditional medical evaluation.
So physicians face a genuine dilemma: animal studies consistently show benefits with minimal side effects, but without rigorous human trials, they can’t confidently predict outcomes for their patients. They can either dismiss peptides entirely or acknowledge that absence of evidence differs from evidence of absence. Neither approach feels satisfying.
The Pharmaceutical Industry’s Invisible Hand
Here’s something they don’t teach you in medical school: pharmaceutical companies heavily influence what physicians learn.
Drug companies fund research that becomes curriculum content. They sponsor continuing education courses and conferences. They provide educational materials to training programs. This isn’t inherently sinister, but it creates obvious incentives favoring patented pharmaceuticals over compounds that can’t be monetized.
Many therapeutic peptides face commercialization challenges because they’re derived from naturally occurring sequences that can’t be patented. Without patent protection, no company will invest the hundreds of millions required for clinical trials leading to regulatory approval.
This means BPC-157—despite over 100 animal studies—has never undergone the rigorous testing that would make it standard medical knowledge. The peptide sequence occurs naturally in human gastric juice. You can’t patent that. So no one funds the trials.
Meanwhile, physicians learn extensively about patented drugs with substantial marketing budgets while remaining completely unaware of potentially valuable compounds that lack commercial sponsors.
Your Doctor Doesn’t Have Time
Even if physicians wanted to learn about peptides independently, practical constraints get in the way.
Canadian family doctors see 30-40 patients daily. Between consultations, they review test results, respond to messages, complete documentation, and handle administrative tasks. The average family physician works 50-60 hours weekly yet still struggles to keep pace.
Continuing medical education requirements ensure competency in primary practice areas—diabetes management, cardiovascular risk, cancer screening. Peptide therapeutics fall outside mandated learning unless physicians actively pursue this knowledge on their own time.
Medical literature grows exponentially. Over 3 million articles publish annually. No physician can read even a fraction of this output. Filtering systems help, but they lag behind emerging research and focus on established treatments.
You, researching BPC-157 for a personal injury, might spend 20 hours reading studies and participating in online discussions. Your physician lacks 20 hours to dedicate to any single topic—especially one without direct relevance to most of their patient panel.
The Specialization Problem
Modern medicine fragments into specialties, each with its own knowledge base. This creates expertise in narrow domains while limiting awareness of developments elsewhere.
Endocrinologists understand peptide hormones intimately. They prescribe insulin, GLP-1 receptor agonists, and other peptide-based treatments. But most Canadians receive primary care from family physicians whose training emphasized breadth over depth.
These clinicians must know something about nearly everything. Peptide therapeutics fall into the specialist category even though patient interest spans general practice. The result is a knowledge asymmetry that reverses traditional medical relationships.
Historically, doctors possessed specialized knowledge patients lacked. With peptides, patients sometimes arrive with more detailed knowledge than their providers—creating awkward dynamics for everyone involved.
Legitimate Safety Concerns
When physicians express hesitation about peptides, they often raise valid quality and safety issues that patients may not have fully considered.
Quality varies dramatically across suppliers. Research-grade peptides sold for laboratory use may contain impurities, degradation products, or incorrect concentrations. Without pharmaceutical-grade manufacturing standards, batch-to-batch consistency can’t be guaranteed.
Stability presents ongoing challenges. Peptides degrade through hydrolysis, oxidation, and aggregation. Proper storage requires specific temperature ranges and protection from light. Patients handling their own peptides may unknowingly administer degraded products.
Contamination risks exist throughout unregulated supply chains. Bacterial endotoxins in injectable products can cause serious reactions. Heavy metal contamination poses long-term health risks. Testing for these contaminants requires analytical capabilities most consumers can’t verify.
Drug interactions remain poorly characterized. The absence of interaction data doesn’t indicate safety—it indicates knowledge gaps that conventional drug development would address before approval.
Long-term effects are largely unknown. Animal studies typically evaluate acute or short-term administration. Patients using peptides for months or years face uncertain consequences.
Physicians weighing these uncertainties against potential benefits often conclude that established treatments with known risk profiles represent safer choices. This may frustrate patients who’ve researched extensively, but both perspectives have merit.
When You Know More Than Your Doctor
The internet democratized medical information in ways that challenge traditional healthcare relationships. You can now read the same PubMed abstracts physicians access, browse clinical trial registries, and participate in communities where users share experiences with experimental treatments.
For peptides specifically, this ecosystem includes Reddit communities with thousands of members, detailed vendor websites, YouTube channels featuring peptide-focused physicians, and research summaries accessible to non-specialists. Someone motivated to learn can acquire substantial knowledge without formal medical training.
When these informed patients visit conventional physicians, disconnects emerge. You ask about optimal BPC-157 dosing. Your doctor has never heard of BPC-157. You inquire about combining growth hormone secretagogues with thymosin beta-4. Your physician struggles to recall what these compounds do.
These interactions frustrate both parties. Patients feel dismissed by physicians who can’t engage with their questions. Physicians feel pressured to endorse treatments they can’t properly evaluate.
Some patients respond by seeking care from integrative medicine practitioners or wellness clinics. This fragmentation creates its own problems—primary care physicians may remain unaware of treatments their patients receive elsewhere.
The Canadian Context
Canada’s healthcare system creates unique challenges regarding peptide medicine.
Health Canada takes a conservative approach to novel therapeutics. This regulatory caution protects Canadians from unproven treatments but also limits access to therapies that might benefit specific patients. Compounds widely available elsewhere may be difficult to obtain legally here.
Provincial medical colleges regulate physician practice. A physician prescribing unapproved peptides risks investigation if a patient experiences adverse effects—even if the treatment followed protocols established in international research.
Canadian compounding pharmacies face restrictions on peptide preparation. Following Health Canada guidance issued in 2025, pharmacies compounding certain peptides may face enforcement actions. This limits physician ability to prescribe compounded formulations even when they believe such treatments would help.
The wellness and anti-aging sector operates somewhat separately from conventional healthcare. Clinics offering peptide therapies often require out-of-pocket payment since provincial insurance rarely covers these treatments. This creates access disparities based on financial resources.
What’s Changing
The gap between peptide research and clinical practice is narrowing, albeit slowly.
Major medical schools are developing peptide therapy certification programs. George Washington University partnered with the American Academy of Anti-Aging Medicine to offer accredited courses covering peptide applications across multiple domains.
The success of GLP-1 receptor agonists like semaglutide has forced conventional medicine to engage with peptide therapeutics. When a peptide-based drug becomes first-line therapy for major chronic diseases, medical education must adapt.
Professional organizations are developing resources for member physicians. The Obesity Medicine Association published position statements on compounded peptides that help clinicians navigate this complex space.
Telemedicine enables patients to access specialized providers regardless of location. A Canadian patient interested in peptide therapy can consult with knowledgeable physicians through video calls, expanding options beyond local providers.
Having Productive Conversations
Until medical education catches up, patients and physicians must navigate an imperfect situation.
Approach conversations with realistic expectations. Your family doctor probably doesn’t have detailed knowledge about specific peptides. This reflects systemic gaps, not individual incompetence.
Bring quality information. Peer-reviewed studies carry more weight than forum posts or vendor websites. Printing relevant PubMed studies allows your physician to evaluate evidence rather than relying on secondhand descriptions.
Understand their constraints. Your doctor can’t prescribe treatments they believe are unsafe or illegal regardless of your preferences. They face professional obligations that may prevent supporting peptide use even if they find the research compelling.
Consider seeking specialist providers for specific questions while maintaining relationships with primary care providers for general health needs. Different providers serve different purposes.
Be prepared for honest answers that might disappoint you. A physician who says they can’t help with peptide therapy isn’t necessarily dismissing your concerns—they may be acknowledging limitations in their training or practice scope.
Frequently Asked Questions
Why does my doctor seem uncomfortable when I ask about peptides?
Physicians are trained to practice evidence-based medicine, which requires strong clinical trial data before recommending treatments. Most therapeutic peptides lack this level of evidence. Additionally, your doctor likely received minimal peptide training during medical school and residency. Their discomfort often reflects honest acknowledgment that they can’t evaluate treatments outside their expertise.
Can my family doctor prescribe peptides in Canada?
Canadian physicians can legally prescribe some peptides that have received Health Canada approval, such as insulin and certain GLP-1 receptor agonists. However, many peptides popular in wellness communities haven’t received approval for any indication. Physicians prescribing unapproved compounds assume legal and professional risks that may influence their willingness to do so.
Where can I find a doctor who understands peptides?
Physicians specializing in anti-aging medicine, integrative medicine, or sports medicine often have more peptide knowledge than general practitioners. Organizations like the American Academy of Anti-Aging Medicine certify physicians in peptide therapy. Telemedicine services can connect Canadian patients with specialists regardless of location.
Should I tell my doctor if I’m using peptides from other sources?
Yes. Even if your primary care physician can’t help you optimize peptide protocols, they need complete information about your health practices to provide safe care. Peptides can interact with medications and affect diagnostic tests. Withholding information compromises their ability to help you.
Will Health Canada approve more peptides in the future?
Health Canada approves drugs based on clinical trial evidence demonstrating safety and efficacy. As peptide research advances and more compounds complete rigorous human trials, some may receive approval. The timeline depends on pharmaceutical company investment, which depends on commercial viability. Peptides that can’t be patented face reduced incentives for expensive trials.
How can I discuss peptide research with my doctor productively?
Bring peer-reviewed research rather than forum posts or vendor claims. Acknowledge the limitations of available evidence while explaining why you find it compelling. Ask what additional evidence would change their perspective. Frame discussions as collaborative exploration rather than confrontational advocacy.
Glossary
Amino Acid: Organic molecules that serve as building blocks for peptides and proteins.
Biologic: A therapeutic product derived from living organisms. In regulatory terms, peptides with more than 40 amino acids are typically classified as biologics.
BPC-157: Body Protection Compound-157, a synthetic 15-amino acid peptide derived from a protein found in human gastric juice. Research suggests tissue protective and healing properties.
Compounding Pharmacy: A pharmacy that prepares customized medications tailored to individual patient needs.
CME (Continuing Medical Education): Educational activities physicians complete after formal training to maintain and expand their knowledge.
Evidence-Based Medicine: An approach integrating the best available research evidence with clinical expertise and patient values.
GLP-1 Receptor Agonist: A class of medications mimicking the glucagon-like peptide-1 hormone. Includes semaglutide and tirzepatide.
Growth Hormone Secretagogue: Compounds that stimulate growth hormone release from the pituitary gland. Examples include sermorelin, CJC-1295, and ipamorelin.
Health Canada: The federal department responsible for regulating drugs, biologics, and therapeutic products.
Integrative Medicine: A healing-oriented approach combining conventional treatments with complementary therapies.
Peptide: A short chain of amino acids linked by peptide bonds, generally containing fewer than 40-50 amino acids.
Preclinical Research: Laboratory studies conducted before human clinical trials, typically involving cell cultures and animal models.
Randomized Controlled Trial (RCT): A study design where participants are randomly assigned to treatment or comparison groups. Considered the gold standard for evaluating interventions.
Research Chemical: A compound sold for laboratory research purposes that hasn’t received regulatory approval for human therapeutic use.
Semaglutide: A GLP-1 receptor agonist peptide approved for treating type 2 diabetes and obesity. Sold under brand names including Ozempic, Wegovy, and Rybelsus.
References
Adams KM, Kohlmeier M, Zeisel SH. Nutrition education in U.S. medical schools: latest update of a national survey. Academic Medicine. 2010;85(9):1537-1542.
Sikiric P, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide. Pharmaceuticals. 2025;18(2):185.
George Washington University School of Medicine. Peptide Therapy Certification Program.
Disclaimer: This article is provided for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any health condition. Peptide compounds discussed in this article may not be approved for human therapeutic use by Health Canada. Always consult with qualified healthcare professionals before making decisions about your health.
